Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.
Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).
Seoul National University Children's Hospital, Seoul, Korea, Republic of
Guang An Men Hospital China Academy of Chinese Medical Sciences, Beijing, Beijing, China
Jilin Province People's Hospital, Changchun, Jilin, China
Ningxia Hui Autonomous Region's Hospital, Yinchuan, Ningxia, China
Chonbuk National University Hospital, Jeonju, Jeollabukdo, Korea, Republic of
McLean Hospital, Belmont, Massachusetts, United States
University of North Carolina, Chapel Hill, North Carolina, United States
National Clinical Research Center for Kidney Disease, State Key Laboratory of Kidney Disease, Department of Nephrology, Chinese PLA General Hospital, Beijing, Beijing, China
Beijing Friendship,Capital Medical University, Beijing, Beijing, China
Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, Beijing, China
NIH Clinical Center, Bethesda, Maryland, United States
UCSF, San Francisco, California, United States
Hennepin County Medical Center, Minneapolis, Minnesota, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.